Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

NCT07079644 · clinicaltrials.gov ↗

COMPLETED

Status

678

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Melanoma

Interventions

BIOLOGICAL: Nivolumab + Relatlimab
BIOLOGICAL: Nivolumab + Ipilimumab
BIOLOGICAL: Immunotherapy monotherapy
DRUG: BRAF/MEK inhibitors

Sponsor

Bristol-Myers Squibb